Skip to main
GKOS

Glaukos (GKOS) Stock Forecast & Price Target

Glaukos (GKOS) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 58%
Buy 33%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Glaukos is a Buy-rated ophthalmic pharmaceutical and medical technology company with significant growth potential, backed by its iDose TR sustained-release drug delivery implant and its positive Epioxa survey checks. Despite potential headwinds from the proposed LCD requirements, the company's strong portfolio of products for glaucoma and corneal disorders, along with its innovative pipeline, make it a promising investment opportunity. With double-digit revenue growth expected and a price target of $150 based on an EV/sales multiple of 10.5x 2027E revenue, Glaukos is poised for success in the ophthalmic market.

Bears say

Glaukos is facing multiple headwinds that could negatively impact their revenues and stock performance. These include potential LCD restrictions for their iDose TR implant, which is their main source of revenue, the competitive and crowded MIGS market, potential reimbursement challenges, and slow adoption of their new medication, Epioxa. The proposed LCD restrictions may limit their market reach and slow down their growth, while the competitive landscape and reimbursement challenges could affect their existing products. Additionally, slow adoption of Epioxa could result in lower revenues and hinder their plans for growth. These factors could lead to a decline in their stock price and may make them a risky investment option.

Glaukos (GKOS) has been analyzed by 12 analysts, with a consensus rating of Buy. 58% of analysts recommend a Strong Buy, 33% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Glaukos (GKOS) Forecast

Analysts have given Glaukos (GKOS) a Buy based on their latest research and market trends.

According to 12 analysts, Glaukos (GKOS) has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $177, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $177, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Glaukos (GKOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.